Phio Pharmaceuticals Q1 2024 net loss narrows to $2.2M; cash at $6.5M

Phio Pharmaceuticals Corp.

2024-Q1 EPS reported -$0.47

Cash of $6.5M at March 31, 2024, down from $8.5M at Dec 31, 2023.
Net loss of $2.2M for Q1 2024 vs $3.6M in prior-year quarter; R&D expenses fell 46% to $1.1M.
Phase 1b trial of PH-762 in skin cancers has enrolled 3 patients at 4 U.S. sites.
USPTO granted patents for INTASYL compounds RXI-185 and RXI-231 targeting age-related skin disorders.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Phio Pharmaceuticals Corp. reported the three months ended March 31, 2024 results: net income Net loss was $2.2 million for the three months ended March 31, 2024.

Period: the three months ended March 31, 2024
Net income: Net loss was $2.2 million for the three months ended March 31, 2024
Result: reported results

Exact text from the filing

On May 9, 2024, Phio Pharmaceuticals Corp. (the “Company”) reported its financial results for the period ended March 31, 2024.

View on SEC.gov

1052 earnings releases filed in the last 30 days. Browse all earnings releases →

Phio Pharmaceuticals Corp. filing history →

Source: SEC EDGAR

accession 0001683168-24-003178

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.